Protein kinase inhibitor nanoparticle therapeutic - Amgen/Pfizer

Drug Profile

Protein kinase inhibitor nanoparticle therapeutic - Amgen/Pfizer

Alternative Names: Kinase Inhibitor Nanomedicine - Amgen/Pfizer

Latest Information Update: 24 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen; BIND Biosciences
  • Developer Amgen; BIND Therapeutics
  • Class
  • Mechanism of Action Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 02 Jul 2014 Amgen and BIND Therapeutics terminate terminate their agreement for the protein kinase inhibitor nanoparticle therapeutic
  • 02 Jul 2014 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
  • 03 Apr 2013 BIND Biosciences is now called BIND Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top